In briefing docs released ahead of Tuesday's meeting of the FDA's Arthritis Advisory Committee, reviewers appeared favorable toward Thousand Oaks, Calif.-based Amgen Inc.'s ABP-501, a biosimilar version of Humira (adalimumab), the top-selling drug from Abbvie Inc., of North Chicago.